AHCO
Wall Street’s not exactly pounding the table
AdaptHealth is getting the classic analyst treatment: not a full-on love letter, but not a breakup text either. Six analysts now average out to a “Moderate Buy” on the home medical equipment provider, with a $13.50 12-month price target.
That matters because it gives you a quick read on sentiment: the Street thinks there’s upside, just maybe not the kind that sends people sprinting for the doors or the champagne.
The catch? The last quarter was messy
Before anyone gets too cozy, AdaptHealth’s latest earnings were a bit of a faceplant. The company reported EPS of -$0.76, badly missing the $0.34 estimate, even though revenue of $846.3 million came in a touch ahead of expectations.
That mix is the financial version of saying, “The dinner was great, but the kitchen was on fire.” Sales held up decently, but profitability didn’t, and investors tend to care a lot when the bottom line goes missing in action.
Why investors should care
The analyst consensus suggests there’s still belief in the story, and insider buying adds a little extra seasoning. Major shareholder Richard M. Cashin Jr. bought 447,100 shares at $9.91 apiece, a pretty loud vote of confidence from someone with skin in the game.
Big picture: analysts are saying the stock may still have room to run, but the company needs to prove it can turn revenue into actual earnings instead of just expensive stress.